Lipocalin 2 in the pathogenesis of fatty liver disease and nonalcoholic steatohepatitis

Clinical Lipidology

Volumn 10, Issue 1, 2015, Pages 47-67

  Asimakopoulou, Anastasia ^a   Weiskirchen, Ralf ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

FABP; fatty liver disease; insulin resistance; LCN2; lipocalin; NASH; NF B; NGAL; OXPAT; perlipin; PLIN5; RBP

Indexed keywords

ADIPOCYTOKINE; FATTY ACID BINDING PROTEIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; RETINOL BINDING PROTEIN;

BROWN ADIPOSE TISSUE; CELL STRESS; FATTY LIVER; HUMAN; HYDROPHOBICITY; INFLAMMATION; NONALCOHOLIC FATTY LIVER; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TRANSPORT; REVIEW; SEQUENCE HOMOLOGY; UPREGULATION;

BACTERIA (MICROORGANISMS);

EID: 84924210501     PISSN: 17584299     EISSN: 17584302     Source Type: Journal    
DOI: 10.2217/clp.14.65     Document Type: Review

References (110)

1. Ganfornina MD, Gutiérrez G, Bastiani M, Sánchez D. A phylogenetic analysis of the lipocalin protein family. Mol. Biol. Evol. 17, 114-126 (2000).
2. Pervaiz S, Brew K. Homology of β-lactoglobulin, serum retinol-binding protein, and protein HC. Science 228, 335-337 (1985).
3. Pervaiz S, Brew K. Homology and structure-function correlations between alpha 1-acid glycoprotein and serum retinol-binding protein and its relatives. FASEB J. 1, 209-214 (1987).
4. Flower DR, North AC, Attwood TK. Mouse oncogene protein 24p3 is a member of the lipocalin protein family. Biochem. Biophys. Res. Commun. 180, 69-74 (1991).
5. Flower DR. The lipocalin protein family: structure and function. Biochem. J. 318, 1-14 (1996).
6. Godovac-Zimmermann J. The structural motif of β-lactoglobulin and retinol-binding protein: a basic framework for binding and transport of small hydrophobic molecules? Trends Biochem. Sci. 13, 64-66 (1988).
7. Cowan SW, Newcomer ME, Jones TA. Crystallographic refinement of human serum retinol binding protein at 2A resolution. Proteins 8, 44-61 (1990).
8. Newcomer ME, Ong DE. Plasma retinol binding protein: structure and function of the prototypic lipocalin. Biochim. Biophys. Acta 1482, 57-64 (2000).
9. Matarese V, Buelt MK, Chinander LL, Bernlohr DA. Purification of adipocyte lipid-binding protein from human and murine cells. Methods Enzymol. 189, 363-369 (1990).
10. Cianci M, Rizkallah PJ, Olczak A et al. The molecular basis of the coloration mechanism in lobster shell: betacrustacyanin at 3.2-A resolution. Proc. Natl Acad. Sci. USA 99, 9795-9800 (2002).
11. Marchese S, Pes D, Scaloni A, Carbone V, Pelosi P. Lipocalins of boar salivary glands binding odours and pheromones. Eur. J. Biochem. 252, 563-568 (1998).
12. Beynon RJ, Hurst JL. Multiple roles of major urinary proteins in the house mouse, Mus domesticus. Biochem. Soc. Trans. 31, 142-146 (2003).
13. Fuentes-Prior P, Noeske-Jungblut C, Donner P, Schleuning WD, Huber R, Bode W. Structure of the thrombin complex with triabin, a lipocalin-like exosite-binding inhibitor derived from a triatomine bug. Proc. Natl Acad. Sci. USA 94, 11845-11850 (1997).
14. Andersen JF, Weichsel A, Balfour CA, Champagne DE, Montfort WR. The crystal structure of nitrophorin 4 at 1.5 A resolution: transport of nitric oxide by a lipocalin-based heme protein. Structure 6, 1315-1327 (1998).
15. Lögdberg L, Wester L. Immunocalins: a lipocalin subfamily that modulates immune and inflammatory responses. Biochim. Biophys. Acta 1482, 284-297 (2000).
16. Multiple Sequence Alignment by CLUSTALW. www.genome.jp/tools/clustalw
17. Coles M, Diercks T, Muehlenweg B et al. The solution structure and dynamics of human neutrophil gelatinaseassociated lipocalin. J. Mol. Biol. 289, 139-157 (1999).
18. Holmes MA, Paulsene W, Jide X, Ratledge C, Strong RK. Siderocalin [Lcn 2] also binds carboxymycobactins, potentially defending against mycobacterial infections through iron sequestration. Structure 13, 29-41 (2005).
19. Motani A, Wang Z, Conn M, Siegler K et al. Identification and characterization of a non-retinoid ligand for retinol-binding protein 4 which lowers serum retinol-binding protein 4 levels in vivo. J. Biol. Chem. 284, 7673-7680 (2009).
20. The RCSB Protein Data Bank (PDB). www.rcsb.org
21. Carson M. Ribbons. Meth. Enzymol. 277, 493-505 (1997).
22. Suzuki K, Lareyre JJ, Sánchez D et al. Molecular evolution of epididymal lipocalin genes localized on mouse chromosome 2. Gene 339, 49-59 (2004).
23. Kjeldsen L, Johnsen AH, Sengeløv H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J. Biol. Chem. 268, 10425-10432 (1993).
24. Human Gene Nomenclature Committee (HUGO). www.genenames.org
25. Xu SY, Carlson M, Engström A, Garcia R, Peterson CG, Venge P. Purification and characterization of a human neutrophil lipocalin (HNL) from the secondary granules of human neutrophils. Scand. J. Clin. Lab. Invest. 54, 365-376 (1994).
26. Triebel S, Bläser J, Reinke H, Tschesche H. A 25 kDa α 2-microglobulin-related protein is a component of the 125 kDa form of human gelatinase. FEBS Lett. 314, 386-388 (1992).
27. Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol. Cell. 10, 1033-1043 (2002).
28. Chan P, Simon-Chazottes D, Mattei MG, Guenet JL, Salier JP. Comparative mapping of lipocalin genes in human and mouse: the four genes for complement C8 gamma chain, prostaglandin-D-synthase, oncogene-24p3, and progestagen-associated endometrial protein map to HSA9 and MMU2. Genomics 23, 145-150 (1994).
29. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182 (1987).
30. Liu Q, Ryon J, Nilsen-Hamilton M. Uterocalin: a mouse acute phase protein expressed in the uterus around birth. Mol. Reprod. Dev. 46, 507-514 (1997).
31. Davis TR, Tabatabai L, Bruns K, Hamilton RT, Nilsen-Hamilton M. Basic fibroblast growth factor induces 3T3 fibroblasts to synthesize and secrete a cyclophilin-like protein and β2-microglobulin. Biochim. Biophys. Acta 1095, 145-152 (1991).
32. Stoesz SP, Gould MN. Overexpression of neu-related lipocalin (NRL) in neu-initiated but not ras or chemically initiated rat mammary carcinomas. Oncogene 11, 2233-2241 (1995).
33. Roy AK, Neuhaus OW. Identification of rat urinary proteins by zone and immunoelectrophoresis. Proc. Soc. Exp. Biol. Med. 121, 894-899 (1966).
34. Kurtz DT, Feigelson P. Multihormonal induction of hepatic α2u-globulin mRNA as measured by hybridization to complementary DNA. Proc. Natl Acad. Sci. USA 74, 4791-4795 (1977).
35. Drickamer K, Kwoh TJ, Kurtz DT. Amino acid sequence of the precursor of rat liver α 2 micro-globulin. J. Biol. Chem. 256, 3634-3666 (1981).
36. Bundgaard JR, Sengeløv H, Borregaard N, Kjeldsen L. Molecular cloning and expression of a cDNA encoding NGAL: a lipocalin expressed in human neutrophils. Biochem. Biophys. Res. Commun. 202, 1468-1475 (1994).
37. Nielsen BS, Borregaard N, Bundgaard JR, Timshel S, Sehested M, Kjeldsen L. Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut 38, 414-420 (1996).
38. Strong RK, Bratt T, Cowland JB, Borregaard N, Wiberg FC, Ewald AJ. Expression, purification, crystallization and crystallographic characterization of dimeric and monomeric human neutrophil gelatinase associated lipocalin [NGAL]. Acta Crystallogr. D Biol. Crystallogr. 54, 93-95 (1998).
39. Goetz DH, Willie ST, Armen RS, Bratt T, Borregaard N, Strong RK. Ligand preference inferred from the structure of neutrophil gelatinase associated lipocalin. Biochemistry 39, 1935-1941 (2000).
40. Yang J, Goetz D, Li JY, Wang W et al. An iron delivery pathway mediated by a lipocalin. Mol. Cell. 10, 1045-1056 (2002).
41. Flo TH, Smith KD, Sato S, Rodriguez DJ, Holmes MA, Strong RK, Akira S, Aderem A. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 432, 917-921 (2004).
42. Berger T, Togawa A, Duncan GS et al. Lipocalin 2-deficient mice exhibit increased sensitivity to Escherichia coli infection but not to ischemia-reperfusion injury. Proc. Natl Acad. Sci. USA 103, 1834-1839 (2006).
43. Hvidberg V, Jacobsen C, Strong RK, Cowland JB, Moestrup SK, Borregaard N. The endocytic receptor megalin binds the iron transporting neutrophil-gelatinase-associated lipocalin with high affinity and mediates its cellular uptake. FEBS Lett. 579, 773-777 (2005).
44. Devireddy LR, Gazin C, Zhu X, Green MR. A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell 123, 1293-1305 (2005).
45. Fang WK, Xu LY, Lu XF et al. A novel alternative spliced variant of neutrophil gelatinase-associated lipocalin receptor in oesophageal carcinoma cells. Biochem J. 403, 297-303 (2007).
46. Jiang W, Constante M, Santos MM. Anemia upregulates lipocalin 2 in the liver and serum. Blood Cells Mol. Dis. 41, 169-174 (2008).
47. Bykov I, Junnikkala S, Pekna M, Lindros KO, Meri S. Effect of chronic ethanol consumption on the expression of complement components and acute-phase proteins in liver. Clin. Immunol. 124, 213-220 (2007).
48. Sunil VR, Patel KJ, Nilsen-Hamilton M, Heck DE, Laskin JD, Laskin DL. Acute endotoxemia is associated with upregulation of lipocalin 24p3/Lcn2 in lung and liver. Exp. Mol. Pathol. 83. 177-187 (2007).
49. Borkham-Kamphorst E, van de Leur E, Zimmermann HW et al. Protective effects of lipocalin-2 [LCN2] in acute liver injury suggest a novel function in liver homeostasis. Biochim. Biophys. Acta 1832, 660-673 (2013).
50. Labbus K, Henning M, Borkham-Kamphorst E et al. Proteomic profiling in Lipocalin 2 deficient mice under normal and inflammatory conditions. J. Proteomics 78, 188-196 (2013
51. El Moety HA, El Sharkawy RM, El Menem Hussein NA. Lipocalin: A novel diagnostic marker for hepatocellular carcinoma in chronic liver disease patients in Egypt. Int. J. Clin. Med. 4, 440-450 (2013).
52. Borkham-Kamphorst E, Drews F, Weiskirchen R. Induction of lipocalin-2 expression in acute and chronic experimental liver injury moderated by pro-inflammatory cytokines interleukin-1β through nuclear factor-κB activation. Liver Int. 31, 656-665 (2011).
53. Auguet T, Terra X, Quintero Y et al. Liver lipocalin 2 expression in severely obese women with non alcoholic fatty liver disease. Exp. Clin. Endocrinol. Diabetes 121, 119-124 (2013).
54. Semba T, Nishimura M, Nishimura S et al. The FLS [fatty liver Shionogi] mouse reveals local expressions of lipocalin-2, CXCL1 and CXCL9 in the liver with non-alcoholic steatohepatitis. BMC Gastroenterol. 13, 120 (2013).
55. Ye Z, Wang S, Yang Z et al. Serum lipocalin-2, cathepsin S and chemerin levels and nonalcoholic fatty liver disease. Mol. Biol. Rep. 41, 1317-1323 (2014).
56. Alwahsh SM, Xu M, Seyhan HA, Ahmad S, Mihm S, Ramadori G, Schultze FC. Diet high in fructose leads to an overexpression of lipocalin-2 in rat fatty liver. World J. Gastroenterol. 20, 1807-1821 (2014).
57. Tekkesin N, Taga Y, Ibrisim D, Gündogan N. Urinary neutrophil gelatinase-associated lipocalin [uNGAL] levels in patients with nonalcoholic fatty liver disease. Interv. Med. Appl. Sci. 4, 132-138 (2012).
58. Guo H, Jin D, Zhang Y et al. Lipocalin-2 deficiency impairs thermogenesis and potentiates diet-induced insulin resistance in mice. Diabetes 59, 1376-1385 (2010).
59. Jin D, Guo H, Bu SY et al. Lipocalin 2 is a selective modulator of peroxisome proliferator-activated receptor-γ activation and function in lipid homeostasis and energy expenditure. FASEB J. 25, 754-764 (2011).
60. Asimakopoulou A, Borkham-Kamphorst E, Henning M et al. Lipocalin-2 [LCN2] regulates PLIN5 expression and intracellular lipid droplet formation in the liver. Biochim. Biophys. Acta 1841, 1513-1524 (2014).
61. Sultan S, Cameron S, Ahmad S et al. Serum Lipocalin2 is a potential biomarker of liver irradiation damage. Liver Int. 33, 459-468 (2013).
62. AbdulHameed MD, Tawa GJ, Kumar K et al. Systems level analysis and identification of pathways and networks associated with liver fibrosis. PLoS ONE 9(11), e112193 (2014).
63. Xu MJ, Feng D, Wu H et al. The liver is the major source of elevated serum lipocalin-2 levels after bacterial infection or partial hepatectomy: a critical role for IL-6/STAT3. Hepatology doi:10.1002/hep.27447 (2014) (Epub ahead of print).
64. Kienzl-Wagner K, Moschen AR, Geiger S et al. The role of lipocalin-2 in liver regeneration. Liver Int. doi:10.1111/liv.12634 (2014) (Epub ahead of print).
65. Scheiermann P, Bachmann M, Goren I, Zwissler B, Pfeilschifter J, Mühl H. Application of interleukin-22 mediates protection in experimental acetaminophen-induced acute liver injury. Am. J. Pathol. 182, 1107-1113 (2013).
66. Lee HJ, Lee EK, Lee KJ, Hong SW, Yoon Y, Kim JS. Ectopic expression of neutrophil gelatinase-associated lipocalin suppresses the invasion and liver metastasis of colon cancer cells. Int. J. Cancer 118, 2490-2497 (2006).
67. Lee EK, Kim HJ, Lee KJ et al. Inhibition of the proliferation and invasion of hepatocellular carcinoma cells by lipocalin 2 through blockade of JNK and PI3K/Akt signaling. Int. J. Oncol. 38, 325-333 (2011).
68. Kim JW, Lee SH, Jeong SH et al. Increased urinary lipocalin-2 reflects matrix metalloproteinase-9 activity in chronic hepatitis C with hepatic fibrosis. Tohoku J. Exp. Med. 222, 319-327 (2010).
69. Roth GA, Nickl S, Lebherz-Eichinger D et al. Lipocalin-2 serum levels are increased in acute hepatic failure. Transplant Proc. 45, 241-244 (2013).
70. Sultan S, Pascucci M, Ahmad S et al. Lipocalin-2 is a major acute-phase protein in a rat and mouse model of sterile abscess. Shock 37, 191-196 (2012).
71. Roudkenar MH, Kuwahara Y, Baba T et al. Oxidative stress induced lipocalin 2 gene expression: addressing its expression under the harmful conditions. J. Radiat. Res. 48, 39-44 (2007).
72. Lai HS, Wu YM, Lai SL, Lin WH. Lipocalin-2 gene expression during liver regeneration after partial hepatectomy in rats. Int. J. Surg. 11, 314-318 (2013).
73. Mishra J, Ma Q, Prada A et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J. Am. Soc. Nephrol. 14, 2534-2543 (2003).
74. Mishra J, Mori K, Ma Q, Kelly C, Barasch J, Devarajan P. Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am. J. Nephrol. 24, 307-315 (2004).
75. Mishra J, Dent C, Tarabishi R et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 365, 1231-1238 (2005).
76. Niemann CU, Walia A, Waldman J et al. Acute kidney injury during liver transplantation as determined by neutrophil gelatinase-associated lipocalin. Liver Transpl. 15, 1852-1860 (2009).
77. Bartsch S, Tschesche H. Cloning and expression of human neutrophil lipocalin cDNA derived from bone marrow and ovarian cancer cells. FEBS Lett. 357, 255-259 (1995).
78. Furutani M, Arii S, Mizumoto M, Kato M, Imamura M. Identification of a neutrophil gelatinase-associated lipocalin mRNA in human pancreatic cancers using a modified signal sequence trap method. Cancer Lett. 122, 209-214 (1998).
79. Friedl A, Stoesz SP, Buckley P, Gould MN. Neutrophil gelatinase-associated lipocalin in normal and neoplastic human tissues. Cell type-specific pattern of expression. Histochem. J. 31, 433-441 (1999).
80. Liu Q, Nilsen-Hamilton M. Identification of a new acute phase protein. J. Biol. Chem. 270, 22565-22570 (1995).
81. Yan QW, Yang Q, Mody N et al. The adipokine lipocalin 2 is regulated by obesity and promotes insulin resistance. Diabetes 56, 2533-2540 (2007). •In this report a connection of LCN2 and formation of insulin resistance was established in murine models.
82. Wang Y, Lam KS, Kraegen EW et al. Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin. Chem. 53, 34-41 (2007).
83. Auguet T, Quintero Y, Terra X et al. Upregulation of lipocalin 2 in adipose tissues of severely obese women: positive relationship with proinflammatory cytokines. Obesity (Silver Spring) 19, 2295-2300 (2011).
84. Zhang Y, Foncea R, Deis JA, Guo H, Bernlohr DA, Chen X. Lipocalin 2 expression and secretion is highly regulated by metabolic stress, cytokines, and nutrients in adipocytes. PLoS ONE 9, e96997 (2014).
85. Scheurer B, Rittner C, Schneider PM. Expression of the human complement C8 subunits is independently regulated by interleukin 1 β, interleukin 6, and interferon γ. Immunopharmacology 38, 167-175 (1997).
86. Horn KD, Wax P, Schneider SM et al. Biomarkers of liver regeneration allow early prediction of hepatic recovery after acute necrosis. Am. J. Clin. Pathol. 112, 351-357 (1999).
87. Boyraz M, Cekmez F, Karaoglu A, Cinaz P, Durak M, Bideci A. Serum adiponectin, leptin, resistin and RBP4 levels in obese and metabolic syndrome children with nonalcoholic fatty liver disease. Biomark. Med. 7, 737-745 (2013).
88. Yan H, Chang X, Xia M et al. Serum retinol binding protein 4 is negatively related to beta cell function in Chinese women with non-alcoholic fatty liver disease: a cross-sectional study. Lipids Health Dis. 12, 157 (2013).
89. Tacke F, Weiskirchen R, Trautwein C. Liver function critically determines serum retinol-binding protein 4 (RBP4) levels in patients with chronic liver disease and cirrhosis. Hepatology 48, 1724-1725 (2008).
90. Zhou Y, Jiang L, Rui L. Identification of MUP1 as a regulator for glucose and lipid metabolism in mice. J. Biol. Chem. 284, 11152-11159 (2009).
91. Cho KW, Zhou Y, Sheng L, Rui L. Lipocalin-13 regulates glucose metabolism by both insulin-dependent and insulin-independent mechanisms. Mol. Cell Biol. 31, 450-457 (2011).
92. Sheng L, Cho KW, Zhou Y, Shen H, Rui L. Lipocalin 13 protein protects against hepatic steatosis by both inhibiting lipogenesis and stimulating fatty acid β-oxidation. J. Biol. Chem. 286, 38128-38135 (2011).
93. Zhou Y, Rui L. Lipocalin 13 regulation of glucose and lipid metabolism in obesity. Vitam. Horm. 91, 369-383 (2013).
94. Westerbacka J, Kolak M, Kiviluoto T et al. Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects. Diabetes 56, 2759-2765 (2007).
95. Guzmán C, Benet M, Pisonero-Vaquero S et al. The human liver fatty acid binding protein [FABP1] gene is activated by FOXA1 and PPAR α; and repressed by C/ EBPα: Implications in FABP1 down-regulation in nonalcoholic fatty liver disease. Biochim. Biophys. Acta 1831, 803-818 (2013).
96. Chien MH, Ying TH, Yang SF et al. Lipocalin-2 induces apoptosis in human hepatocellular carcinoma cells through activation of mitochondria pathways. Cell Biochem. Biophys. 64, 177-186 (2012).
97. Baumeister SE, Völzke H, Marschall P et al. Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation. Gastroenterology 134, 85-94 (2007).
98. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig. Dis. 28, 155-161 (2010).
99. Reddy JK, Rao MS. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am. J. Physiol. Gastrointest. Liver Physiol. 290, 852-858 (2006).
100. Fierbinteanu-Braticevici C, Dina I, Petrisor A, Tribus L, Negreanu L, Carstoiu C. Noninvasive investigations for non alcoholic fatty liver disease and liver fibrosis. World J. Gastroenterol. 16, 4784-4791 (2010).
101. Barr J, Vázquez-Chantada M, Alonso C et al. Liquid chromatography-mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease. J. Proteome Res. 9, 4501-4512 (2010).
102. Myers RP. Noninvasive diagnosis of nonalcoholic fatty liver disease. Ann. Hepatol. 1, S25-S33 (2009).
103. Cheng Q, Ng KT, Xu A et al. The roles of lipocalin-2 in small-for-size fatty liver graft injury. Ann. Surg. 260, 1062-1072 (2014).
104. Sztalryd C, Kimmel AR. Perilipins: lipid droplet coat proteins adapted for tissue-specific energy storage and utilization, and lipid cytoprotection. Biochimie 96, 96-101 (2014).
105. Wang C, Zhao Y, Gao X et al. Perilipin 5 improves hepatic lipotoxicity by inhibiting lipolysis. Hepatology doi:10.1002/ hep.27409 (2014) (Epub ahead of print).
106. Mason RR, Mokhtar R, Matzaris M et al. PLIN5 deletion remodels intracellular lipid composition and causes insulin resistance in muscle. Mol. Metab. 3, 652-663 (2014).
107. Dent CL, Ma Q, Dastrala S et al. Plasma neutrophil gelatinase-associated lipocalin predicts acute kidney injury, morbidity and mortality after pediatric cardiac surgery: a prospective uncontrolled cohort study. Crit. Care 11(6), R127 (2007).
108. Alpha Laboratories Ltd. NGAL the biomarker in renal toxicology. www.alphalabs.co.uk future
109. Zhang Y, Fan Y, Mei Z. NGAL and NGALR overexpression in human hepatocellular carcinoma toward a molecular prognostic classification. Cancer Epidemiol. 36, 294-299 (2012).
110. Granneman JG, Moore HP, Mottillo EP, Zhu Z, Zhou L. Interactions of perilipin-5 (Plin5) with adipose triglyceride lipase. J. Biol. Chem. 286, 5126-5135 (2011).